Healthcare provider profile · identity verified

Matthew J. Fleig, M.D.

Family Practice · ROCHESTER, NY · NPI 1760444814

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	605	168
Lisinopril	Lisinopril	248	74
Metoprolol Succinate	Metoprolol Succinate	224	65
Omeprazole	Omeprazole	193	53
Losartan Potassium	Losartan Potassium	185	53
Hydrochlorothiazide	Hydrochlorothiazide	175	51
Levothyroxine Sodium	Levothyroxine Sodium	173	45
Gabapentin	Gabapentin	136	38
Famotidine	Famotidine	135	34
Glipizide	Glipizide	122	28
Trazodone Hcl	Trazodone Hcl	119	28
Chlorthalidone	Chlorthalidone	96	25
Metformin Hcl	Metformin Hcl	96	29
Simvastatin	Simvastatin	95	30
Amlodipine Besylate	Amlodipine Besylate	94	30
Pantoprazole Sodium	Pantoprazole Sodium	88	26
Zolpidem Tartrate	Zolpidem Tartrate	88	16
Albuterol Sulfate Hfa	Albuterol Sulfate	87	29
Allopurinol	Allopurinol	87	26
Rosuvastatin Calcium	Rosuvastatin Calcium	86	23
Tamsulosin Hcl	Tamsulosin Hcl	75	20
Tramadol Hcl	Tramadol Hcl	75	13
Furosemide	Furosemide	70	19
Sertraline Hcl	Sertraline Hcl	70	20
Citalopram Hbr	Citalopram Hydrobromide	63	17
Paroxetine Hcl	Paroxetine Hcl	63	17
Pravastatin Sodium	Pravastatin Sodium	63	17
Donepezil Hcl	Donepezil Hcl	61	13
Metoprolol Tartrate	Metoprolol Tartrate	60	17
Eliquis	Apixaban	59	15
Pioglitazone Hcl	Pioglitazone Hcl	59	16
Atenolol	Atenolol	53	16
Duloxetine Hcl	Duloxetine Hcl	52	15
Fluoxetine Hcl	Fluoxetine Hcl	48	suppressed
Mirtazapine	Mirtazapine	47	suppressed
Hydralazine Hcl	Hydralazine Hcl	46	14
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	45	15
Torsemide	Torsemide	45	11
Ezetimibe	Ezetimibe	44	12
Spironolactone	Spironolactone	44	12
Venlafaxine Hcl Er	Venlafaxine Hcl	44	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	42	11
Trulicity	Dulaglutide	42	suppressed
Meloxicam	Meloxicam	41	12
Potassium Chloride	Potassium Chloride	40	11
Prednisone	Prednisone	40	15
Fluticasone Propionate	Fluticasone Propionate	38	15
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	36	suppressed
Lovastatin	Lovastatin	36	suppressed
Solifenacin Succinate	Solifenacin Succinate	34	suppressed
Arnuity Ellipta	Fluticasone Furoate	32	suppressed
Carvedilol	Carvedilol	32	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	32	suppressed
Metformin Hcl Er	Metformin Hcl	32	suppressed
Warfarin Sodium	Warfarin Sodium	31	suppressed
Topiramate	Topiramate	29	suppressed
Bupropion Xl	Bupropion Hcl	28	suppressed
Diclofenac Sodium	Diclofenac Sodium	28	suppressed
Amoxicillin	Amoxicillin	26	suppressed
Clopidogrel	Clopidogrel Bisulfate	26	suppressed
Montelukast Sodium	Montelukast Sodium	26	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	25	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	24	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	24	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	23	suppressed
Meclizine Hcl	Meclizine Hcl	23	suppressed
Clonidine Hcl	Clonidine Hcl	22	suppressed
Oxycodone Hcl	Oxycodone Hcl	22	suppressed
Atrovent Hfa	Ipratropium Bromide	21	suppressed
Ozempic	Semaglutide	21	suppressed
Xarelto	Rivaroxaban	21	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	20	20
Oxybutynin Chloride	Oxybutynin Chloride	20	suppressed
Hydrocortisone	Hydrocortisone	19	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	19	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Spiriva Respimat	Tiotropium Bromide	19	suppressed
Celecoxib	Celecoxib	18	suppressed
Nifedipine Er	Nifedipine	18	suppressed
Synthroid	Levothyroxine Sodium	18	suppressed
Finasteride	Finasteride	17	suppressed
Glipizide Er	Glipizide	17	suppressed
Pregabalin	Pregabalin	17	suppressed
Diazepam	Diazepam	16	suppressed
Digoxin	Digoxin	16	suppressed
Irbesartan	Irbesartan	16	suppressed
Ibuprofen	Ibuprofen	15	suppressed
Methylprednisolone	Methylprednisolone	15	15
Symbicort	Budesonide/Formoterol Fumarate	15	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	15	suppressed
Cephalexin	Cephalexin	14	suppressed
Clobetasol Propionate	Clobetasol Propionate	14	suppressed
Glimepiride	Glimepiride	14	suppressed
Nabumetone	Nabumetone	14	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	14	suppressed
Nystatin	Nystatin	14	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	13	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	13	suppressed
Labetalol Hcl	Labetalol Hcl	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	13	suppressed
Procto-Med Hc	Hydrocortisone	13	suppressed
Clonazepam	Clonazepam	12	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	12	suppressed
Incruse Ellipta	Umeclidinium Bromide	12	suppressed
Lorazepam	Lorazepam	12	suppressed
Methadone Hcl	Methadone Hcl	12	suppressed
Ramipril	Ramipril	12	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	12	suppressed
Tizanidine Hcl	Tizanidine Hcl	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Cefpodoxime Proxetil	Cefpodoxime Proxetil	11	11
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Fenofibrate	Fenofibrate	11	suppressed
Galantamine Hbr	Galantamine Hbr	11	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	11	suppressed
Klayesta	Nystatin	11	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	11	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error